Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring the antifungal potential of -derived stilbenoids and cannabinoids against novel targets through protein interaction profiling.
Front Chem
January 2025
Department of Surgery, Pirogov Russian National Research Medical University, Moscow, Russia.
Cannabinoid and stilbenoid compounds derived from were screened against eight specific fungal protein targets to identify potential antifungal agents. The proteins investigated included Glycosylphosphatidylinositol (GPI), Enolase, Mannitol-2-dehydrogenase, GMP synthase, Dihydroorotate dehydrogenase (DHODH), Heat shock protein 90 homolog (Hsp90), Chitin Synthase 2 (CaChs2), and Mannitol-1-phosphate 5-dehydrogenase (M1P5DH), all of which play crucial roles in fungal survival and pathogenicity. This research evaluates the binding affinities and interaction profiles of selected cannabinoids and stilbenoids with these eight proteins using molecular docking and molecular dynamics simulations.
View Article and Find Full Text PDFBergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations.
Front Pharmacol
January 2025
Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
The natural world is a vast reservoir of exceptionally varied and inventive chemical compositions. Natural products are used as initial compounds to create combinatorial libraries by targeted modifications and then by analyzing their structure-activity connections. This stage is regarded as a crucial milestone in drug discovery and development.
View Article and Find Full Text PDFEpidemiology of Vulvovaginal Candidiasis in Greece: A 2-Year Single-Centre Study.
Mycoses
January 2025
Department of Clinical Microbiology, General Hospital "G. Gennimatas", Athens, Greece.
Background: The epidemiology of vulvovaginal candidiasis (VVC) in Greece remains poorly reported and outdated.
Objectives: We therefore conducted a 2-year retrospective survey to assess the epidemiological aspects of the infection among symptomatic Greek patients.
Patients/methods: High vaginal swab samples were collected from adult women with clinically suspected VVC attending a private diagnostic laboratory in Athens.
Antibacterial activity of selenium nanoparticles/copper oxide (SeNPs/CuO) nanocomposite against some multi-drug resistant clinical pathogens.
BMC Microbiol
January 2025
Clinical microbiology and immunology department, National liver institute, Menoufia University, Shibin el Kom, Egypt.
Background: Recent advances in nanomedicine have derived novel prospects for development of various bioactive nanoparticles and nanocomposites with significant antibacterial and antifungal properties. This study aims to investigate some characteristics of the novel Se-NPs/CuO nanocomposite such as morphological, physicochemical, and optical properties, as well as to assess the antibacterial activity of this fabricated composite in different concentrations against some MDR Gram-positive and Gram-negative clinical bacterial isolates.
Methods: The Se-NPs/CuO nanocomposite was fabricated using the chemical deposition method.
The cardiometabolic safety of dupilumab in atopic dermatitis: A global large-scale cohort study.
Arch Dermatol Res
January 2025
Lűbeck Institute of Experimental Dermatology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Background: A low risk of cardiovascular and metabolic outcomes was found in the randomized clinical trials of dupilumab in atopic dermatitis (AD). Dupilumab-associated real-life long-term cardiometabolic risk relative to other systemic agents is yet to be precisely investigated.
Objective: To assess the risk of cardiometabolic outcomes in patients with AD treated with dupilumab relative to those treated with methotrexate and cyclosporine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!